阿奇霉素序贯疗法联合匹多莫德对支原体肺炎患儿血清炎性因子水平及免疫功能的影响

Abstract
Figure/Table
References (25)
Related Citation (2)

Download: PDF (345 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of sequential treatment with Azithromycin combined with Pidotimod on the levels of serum inflammatory cytokines and immune function in children with Mycoplasma pneumonia. Methods The subjects of 147 children with Mycoplasma pneumonia in the Fourth People's Hospital of Hengshui from January 2016 to December 2016. Randomized divided into control group and research group, including 73 cases of children in the control group, 74 cases of study group. The control group was treated with Azithromycin sequential therapy. The control group was treated with Azithromycin sequential therapy. The study group was treated with Azithromycin sequential therapy combined with Pidotimod. Serum inflammatory factors and immune parameters were compared between the two groups. Results The total effective rate in the study group was 95.95%, which was significantly higher than that in the control group (83.56%) , the difference was statistically significant (P < 0.05) . After treatment, the serum TNF-a [(0.72±0.14) mg/L], IL-4 [(25.14±2.54) ng/L], IL-6 [(7.43±2.42) ng/L], IL-10 [(26.73±2.49) ng/L] of patients in the two groups were significantly lower than the control group [(1.39±0.21) mg/L, (37.26±3.41) ng/L, (12.56±3.29) ng/L, (34.36±3.17) ng/L], the differences between two groups were statistically significant (P < 0.05). After treatment, CD3+ and CD4+ of patients in the study group increased compared with that before treatment, and the level of CD8+ in the study group was significantly lower than that before treatment (P < 0.05), and the study group changed more than the control group, the difference between the groups was statistically significant (P < 0.05). Conclusion Azithromycin sequential therapy combined with Pidotimod treatment has a good therapeutic effect, can effectively improve the patients' inflammatory response and improve the patients′ immune function, it is worth promoting.

Key words： Azithromycin Pidotimod Mycoplasma pneumonia Serum inflammatory cytokines Immune function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Lijie CHEN Yun WANG Tingting

Cite this article:

HU Lijie CHEN Yun WANG Tingting. Effects of Azithromycin sequential therapy combined with Pidotimer on serum inflammatory cytokines and immune function in children with Mycoplasma pneumonia[J]. 中国医药导报, 2018, 15(2): 132-135.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I2/132

[1] 刘娜，陈秀东，尹龙海.阿奇霉素序贯疗法联合双黄连口服液治疗小儿支原体肺炎的临床疗效及其对血清炎性因子水平和免疫功能的影响[J].实用心脑肺血管病杂志，2016，24（9）：94-97.
[2] Qu Y. Effect of Azithromycin Sequential Therapy in the Treatment of Inflammatory Cytokines in Children with Mycoplasma Pneumonia in Children[J]. China Journal of Pharmaceutical Economics，2015，17（4）：354-356..
[3] 陈跃宣，马洪梅.热毒宁联合阿奇霉素对支原体肺炎患儿抗炎、促炎因子及免疫功能的影响[J].海南医学院学报，2014，20（12）：1702-1704.
[4] 程真梅，曹梅，吉山宝.阿奇霉素序贯疗法联合痰热清对小儿支原体肺炎患儿内在作用机制研究[J].海南医学院学报，2017，23（6）：789-792.
[5] Miyashita N，Kawai Y，Akaike H. et al. Transmission of macrolide-resistant Mycoplasma pneumoniae within a family [J]. J Infect Chem，2013，19（6）：1196-1201.
[6] IrohTam PY. Approach to Common Bacterial Infections. Community-Acquired Pneumonia [J]. Pediatric Clinics of North America，2013，60（2）：437-453.
[7] 张欢.山茛菪碱注射液辅助阿奇霉素序贯疗法对支原体肺炎患儿血清学指标的影响[J].海南医学院学报，2016， 22（4）：373-376.
[8] Chen XK. Analyzing Clinical Efficacy of Azithromycin Sequential Therapy in Treatment of Children with Mycoplasma Pneumonia [J]. Guide of China Medicine，2012，13（4）：323-326.
[9] 毛琼，高改兰.阿奇霉素治疗小儿支原体肺炎疗效观察[J].中国医药导报，2011，8（18）：186-187.
[10] 邓永洪，张荣贵，刘红霞，等.难治性肺炎支原体肺炎患儿免疫功能变化及匹多莫德免疫干预作用研究[J].河北医学，2015，17（6）：920-922.
[11] Chen Y. Efficacy of Azithromycin Sequential Therapy in the Treatment Children With Mycoplasma Pneumoniae Pneumonia [J]. China Health Standard Management，2015， 12（21）：114-115.
[12] 王冠，李开为.匹多莫德对支原体肺炎患儿免疫及炎性因子的影响[J].临床肺科杂志，2014，19（5）：823-825.
[13] To KK，Chan KH，Fung YF，et al. Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia [J]. Eur Respir J，2010，36（4）：969-971.
[14] 杨立新.红霉素联合阿奇霉素序贯疗法与单用阿奇霉素治疗小儿支原体肺炎的效果比较[J].中国医药导报，2016， 13（18）：173-176.
[15] Luo Z，Luo J，Liu E. et al. Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children[J]. Pediatr Pulm，2014，49（4）：377-380.
[16] Liping C，Qunwei Z，Jie S，et al. Clinical Analysis of 106 Cases of Mycoplasma Mixed Infections in Children with Pneumonia[C].//Progress in applied sciences，engineering and technology： Selected，peer reviewed papers from the 2014 International Conference on Materials Science and Computational Engineering （ICMSCE 2014），May 20-21，2014，Qingdao，China.2014：1071-1073.
[17] 钟秀梅，邓焰，楚雪梅.炎琥宁治疗对支原体肺炎患儿血清炎性因子和免疫功能的影响[J].海南医学院学报，2015，21（9）：1262-1264.
[18] 陈玲，覃军，胡荆江.哌拉西林舒巴坦联合阿奇霉素治疗儿童支原体肺炎的临床疗效及其对血清炎性因子水平的影响[J].实用心脑肺血管病杂志，2016，24（3）：98-101.
[19] Shen Y，Zhang J，Hu Y，et al. Combination therapy with immune-modulators and moxifloxacin on fulminant macrolide-resistant Mycoplasma pneumoniae infection：A case report [J]. Pediatr Pulm，2013，48（5）：519-522.
[20] 高群英，袁纯，丁国标.阿奇霉素序贯疗法治疗学龄前儿童肺炎支原体感染的疗效、安全性及对炎性因子水平的影响[J].现代中西医结合杂志，2015，14（32）：3549-3551.
[21] Nishikawa A，Mimura K，Kanagawa T，et al. Thrombocytopenia associated with Mycoplasma pneumonia during pregnancy：Case presentation and approach for differential diagnosis [J]. J Obstet Gynaecol Res，2015，41（8）：1273-1277.
[22] 张小云.痰热清注射液联合阿奇霉素序贯治疗小儿支原体肺炎的临床观察[J].中国医药导报，2011，8（28）：56-57.
[23] Kawai Y，Miyashita N，Kubo M，et al. Therapeutic efficacy of macrolides，minocycline，and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients [J]. Antimicrob Agents Ch，2013，57（5）：2252-2258.
[24] Biondi E，McCulloh R，Alverson B，et al. Treatment of mycoplasma pneumonia： A systematic review [J]. Pediatrics，2014，133（6）：1081-1090.
[25] Khan FY， Sayed H. Rhabdomyolysis associated with Mycoplasma pneumoniae pneumonia [J]. Hong Kong Med J，2012，18（3）：247-249.